WealthShield Partners LLC Purchases Shares of 28,111 Edwards Lifesciences Corporation $EW

WealthShield Partners LLC purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 28,111 shares of the medical research company’s stock, valued at approximately $2,543,000.

A number of other large investors have also modified their holdings of EW. Varma Mutual Pension Insurance Co acquired a new position in shares of Edwards Lifesciences during the second quarter valued at about $11,168,000. Westpac Banking Corp purchased a new stake in Edwards Lifesciences during the 2nd quarter worth approximately $412,000. Landscape Capital Management L.L.C. acquired a new position in Edwards Lifesciences during the 2nd quarter valued at approximately $2,053,000. Korea Investment CORP purchased a new position in shares of Edwards Lifesciences in the second quarter worth $40,486,000. Finally, EP Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences in the second quarter worth $3,410,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $89.89 on Friday. The business’s 50-day moving average is $89.21 and its two-hundred day moving average is $84.67. The company has a market capitalization of $51.76 billion, a P/E ratio of 51.66, a P/E/G ratio of 2.26 and a beta of 0.85. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the previous year, the firm posted $0.67 EPS. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. The trade was a 3.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on EW. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. UBS Group assumed coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.